Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
European Journal of Cancer Care|January 21, 2021
Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' viewsRuth I Hart, Dorothy Boyle, David A Cameron, et al.
Breast Cancer Research and Treatment|February 14, 2018
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trialKim C Aalders, Nathan Touati, Konstantinos Tryfonidis, et al.
Journal of Cancer Policy|September 7, 2024
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patientsCalum Purdie, Gavin R C Clark, David A Cameron, et al.
Hearing Research|May 24, 2023
Effects of sensorineural hearing loss on formant-frequency discrimination: Measurements and modelsLaurel H Carney, David A Cameron, Kameron B Kinast, et al.
BMC Health Services Research|January 10, 2020
The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregiversRuth I Hart, David A Cameron, Fiona J Cowie, et al.
Neural Development|July 10, 2012
Layer 6 cortical neurons require Reelin-Dab1 signaling for cellular orientation, Golgi deployment, and directed neurite growth into the marginal zoneRyan S O'Dell, Candida J M Ustine, David A Cameron, et al.
Carcinogenesis|December 8, 2005
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cellsFiona McPhillips, Peter Mullen, Kenneth G MacLeod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupRobert J Paridaens, Luc Y Dirix, Louk V Beex, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancerJ Michael Dixon, Lorna Renshaw, Oliver Young, et al.
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
European Journal of Cancer Care|January 21, 2021
Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' viewsRuth I Hart, Dorothy Boyle, David A Cameron, et al.
Breast Cancer Research and Treatment|February 14, 2018
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trialKim C Aalders, Nathan Touati, Konstantinos Tryfonidis, et al.
Journal of Cancer Policy|September 7, 2024
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patientsCalum Purdie, Gavin R C Clark, David A Cameron, et al.
Hearing Research|May 24, 2023
Effects of sensorineural hearing loss on formant-frequency discrimination: Measurements and modelsLaurel H Carney, David A Cameron, Kameron B Kinast, et al.
BMC Health Services Research|January 10, 2020
The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregiversRuth I Hart, David A Cameron, Fiona J Cowie, et al.
Neural Development|July 10, 2012
Layer 6 cortical neurons require Reelin-Dab1 signaling for cellular orientation, Golgi deployment, and directed neurite growth into the marginal zoneRyan S O'Dell, Candida J M Ustine, David A Cameron, et al.
Carcinogenesis|December 8, 2005
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cellsFiona McPhillips, Peter Mullen, Kenneth G MacLeod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupRobert J Paridaens, Luc Y Dirix, Louk V Beex, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancerJ Michael Dixon, Lorna Renshaw, Oliver Young, et al.
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Pageof 14